Partial
Partial / Misaligned
Patient Risk:
Moderate
Summary
Only the ART/embryo implantation indication claim is supported by the provided label excerpts. Other claims (bioidentical/structure identical; abnormal uterine bleeding and estrogen replacement/intact uterus; dosage forms) are not supported by the supplied label text and therefore are treated as unsupported.
Category Scores
Accurate Statements
Progesterone vaginal insert supports embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.
Supported by label section 1 INDICATIONS AND USAGE (and consistent with 12.1 and 14.1 in the provided excerpts).
Unsupported Statements
Xiromed progesterone is a bioidentical hormone.
No supporting language about 'bioidentical' in the provided label excerpts.
Xiromed progesterone has a molecular structure identical to progesterone produced naturally in the human body.
No supporting language about molecular structure or identity in the provided label excerpts.
Xiromed progesterone is a prescription medication approved for use in women for abnormal uterine bleeding due to hormonal imbalance.
The provided label excerpts do not include an indication for abnormal uterine bleeding/hormonal imbalance.
Xiromed progesterone is approved for use as part of hormone therapy in women with an intact uterus who are taking estrogen replacement therapy.
The provided label excerpts do not include an indication for use with estrogen replacement therapy in women with an intact uterus.
Xiromed progesterone is available in various forms, including capsules and vaginal inserts.
The provided label excerpts only address a progesterone vaginal insert; no label support is provided for capsules or 'various forms.'
Progesterone therapy carries potential risks including blood clots.
No safety/boxed warning/adverse reaction language about blood clots is present in the provided label excerpts.
Progesterone therapy carries potential risks including stroke.
No safety/boxed warning/adverse reaction language about stroke is present in the provided label excerpts.
Progesterone therapy carries potential risks including heart attack.
No safety/boxed warning/adverse reaction language about heart attack is present in the provided label excerpts.
Progesterone therapy carries potential risks including certain types of cancer, such as breast cancer, particularly when used in combination with estrogen.
No safety/boxed warning/adverse reaction language about cancer or breast cancer (or estrogen combination context) is present in the provided label excerpts.
Contradictions
Important Omissions
If the intent is to describe on-label dosing/administration, the provided label excerpts specify 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks; the AI claims list did not include or align with these specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about additional indications and potential serious risks (blood clots/stroke/heart attack/cancer) are not verifiable from the supplied label excerpts and could mislead regarding approved uses and labeled risk information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partial / Misaligned
Primary Issue
Most claims are not supported by the provided FDA label excerpts (bioidentical/structure identity, additional indications, product forms, and specific serious risks). Only the ART embryo implantation/early pregnancy indication claim is supported.
Suggested Improvement
Limit claims to the provided on-label indication (ART luteal supplementation for embryo implantation/early pregnancy in infertile women) and avoid stating bioidentical/structure identity, other indications (AUB; estrogen-with-intact-uterus), product-form availability, or specific serious risks unless supported by the provided label sections.